NCT02410499View on ClinicalTrials.gov

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 20, 2015

Primary Completion Date

November 17, 2015

Study Completion Date

November 17, 2015

Conditions

Diabetic Nephropathy

Interventions

DRUG

MLN1202 Placebo

MLN1202 placebo-matching solution for SC injection

DRUG

MLN1202

MLN1202 solution for SC injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY